Analysts Anticipate Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Will Post Earnings of -$2.52 Per Share

Analysts predict that Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating) will post ($2.52) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Biohaven Pharmaceutical’s earnings. The lowest EPS estimate is ($3.59) and the highest is ($0.65). Biohaven Pharmaceutical reported earnings per share of ($4.21) in the same quarter last year, which suggests a positive year-over-year growth rate of 40.1%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Biohaven Pharmaceutical will report full-year earnings of ($8.51) per share for the current financial year, with EPS estimates ranging from ($10.23) to ($6.85). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.79) per share, with EPS estimates ranging from ($6.83) to ($1.14). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Biohaven Pharmaceutical.

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) last announced its quarterly earnings results on Friday, February 25th. The company reported ($3.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.07) by ($0.94). The firm had revenue of $190.01 million during the quarter, compared to analyst estimates of $175.54 million. During the same quarter in the previous year, the company earned ($3.62) EPS. The company’s revenue for the quarter was up 441.1% on a year-over-year basis.

Several brokerages recently weighed in on BHVN. Morgan Stanley dropped their target price on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Mizuho boosted their target price on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the stock a “buy” rating in a research note on Thursday, March 3rd. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Biohaven Pharmaceutical has a consensus rating of “Buy” and a consensus target price of $148.27.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Capital World Investors lifted its position in Biohaven Pharmaceutical by 1.9% during the 4th quarter. Capital World Investors now owns 6,178,009 shares of the company’s stock worth $851,391,000 after acquiring an additional 115,628 shares during the period. BlackRock Inc. lifted its position in Biohaven Pharmaceutical by 0.6% during the 4th quarter. BlackRock Inc. now owns 4,635,280 shares of the company’s stock worth $638,787,000 after acquiring an additional 28,207 shares during the period. Stifel Financial Corp lifted its position in Biohaven Pharmaceutical by 1.9% during the 4th quarter. Stifel Financial Corp now owns 3,049,995 shares of the company’s stock worth $420,319,000 after acquiring an additional 55,650 shares during the period. Marshall Wace LLP lifted its position in Biohaven Pharmaceutical by 3.0% during the 4th quarter. Marshall Wace LLP now owns 2,798,457 shares of the company’s stock worth $385,657,000 after acquiring an additional 80,272 shares during the period. Finally, State Street Corp lifted its position in Biohaven Pharmaceutical by 11.0% during the 4th quarter. State Street Corp now owns 1,647,694 shares of the company’s stock worth $227,069,000 after acquiring an additional 162,764 shares during the period. 88.03% of the stock is owned by institutional investors.

Shares of NYSE:BHVN opened at $90.25 on Friday. Biohaven Pharmaceutical has a 12-month low of $65.24 and a 12-month high of $151.51. The business’s fifty day simple moving average is $112.37 and its 200-day simple moving average is $121.44. The company has a market capitalization of $6.37 billion, a PE ratio of -6.90 and a beta of 1.20.

Biohaven Pharmaceutical Company Profile (Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Read More

Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.